PharmaShots | Incisive News in 3 Shots

Subscribe Now

secondary progressive multiple

Novartis Reports Results of Mayzent (siponimod) in P-III EXPAND Study for Secondary Progressive Multiple Sclerosis

Novartis Reports Results of Mayzent (siponimod) in P-III EXPAND Study for Secondary Progressive Multiple Sclerosis

April 21, 2020

Novartis' Mayzent (siponimod) Receives EC's Approval to Treat Patients with Secondary Progressive Multiple Sclerosis with Active Disease

Novartis' Mayzent (siponimod) Receives EC's Approval to Treat Patients with Secondary Progressive Multiple Sclerosis with Active D...

January 21, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us